Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.72 |
| ▸ | BRD4 | O60885 | 10/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | CSK | P41240 | 1/20 | 0.31 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.31 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542410 | 1.00 | CYP3A4 (0.72) | CYP3A4BRD4CRBNFYNTGFBR1 | |
| SCHEMBL2127754 | 0.88 | CYP3A4 (0.78) | CYP3A4BRD4CRBNFYNTGFBR1 | |
| SCHEMBL1543171 | 0.88 | CYP3A4 (0.78) | CYP3A4BRD4CRBNFYNTGFBR1 | |
| SCHEMBL12675758 | 0.88 | CYP3A4 (0.81) | CYP3A4BRD4CRBNFYNTGFBR1 | |
| SCHEMBL2128074 | 0.84 | CYP3A4 (1.00) | CYP3A4BRD4CRBNEP300 | |
| SCHEMBL2128077 | 0.84 | CYP3A4 (1.00) | CYP3A4BRD4CRBNEP300 | |
| SCHEMBL1542447 | 0.83 | CYP3A4 (0.78) | CYP3A4CRBNFYNTGFBR1ACVR1 | |
| SCHEMBL1764947 | 0.83 | CYP3A4 (0.78) | CYP3A4CRBNFYNTGFBR1ACVR1 | |
| SCHEMBL12675757 | 0.82 | CYP3A4 (0.79) | CYP3A4BRD4CRBNFYNTGFBR1 | |
| SCHEMBL1542574 | 0.81 | CYP3A4 (0.78) | CYP3A4BRD4CRBNFYNTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885BRD4 998/4885CRBN 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.